|
|
|
|
| LEADER |
01867nam a2200241 u 4500 |
| 001 |
EB002002032 |
| 003 |
EBX01000000000000001164933 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Ranibizumab in treating age-related macular degeneration
|h Elektronische Ressource
|c Swedish Council on Health Technology Assessment
|
| 260 |
|
|
|a Stockholm
|b Swedish Council on Health Technology Assessment (SBU)
|c May 21, 2008, 2008
|
| 300 |
|
|
|a 1 PDF file (3 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Macular Degeneration / drug therapy
|
| 653 |
|
|
|a Ranibizumab / therapeutic use
|
| 710 |
2 |
|
|a Statens beredning för medicinsk utvärdering (Sweden)
|
| 740 |
0 |
2 |
|a Ranibizumab för behandling av åldersförändringar i näthinnans gula fläck
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK448014
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Conclusions1. Monthly treatment with ranibizumab has a substantial inhibitory effect on the course of disease compared to photodynamic therapy or sham injection in patients with neovascular age-related macular degeneration - in followup ≤2 years.2. Monthly treatment improves vision to a substantially higher degree in patients treated with ranibizumab compared to those who received photodynamic therapy or sham injection - in followup ≤2 years.3. Scientific evidence is insufficient regarding the effects of treatment when delivered less frequently than once per month, or for periods exceeding 2 years.4. It is unclear whether treatment can be discontinued, or if further treatments are necessary to maintain the effects.5. Scientific evidence is insufficient to assess the cost-effectiveness of the method
|